Meta-Analysis of Trials on Prophylactic Use of Levosimendan in Patients Undergoing Cardiac Surgery
Conclusions Prophylactic use of levosimendan does not appear to reduce the mortality at 30 days or beyond 30 days in patients undergoing cardiac surgery. This lack of benefit was noted irrespective of the LVEF. Graphical abstract
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
More News: Atrial Fibrillation | Cardiovascular & Thoracic Surgery | Computers | Databases & Libraries | Dialysis | Heart Attack | Intensive Care | Men | Statistics | Study | Urology & Nephrology